omniture
I-Mab-天境生物科技(上海)有限公司

Latest News

I-Mab Receives IND Approval from the US FDA to Initiate Clinical Trials for Its Proprietary TJC4, a Potential Global Best-in-Class Anti-CD47 Monoclonal Antibody

SHANGHAI, Jan. 28, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China -based clinical stage bio...

2019-01-28 21:58 469

I-Mab Biopharma Receives U.S. FDA IND Clearance for Proprietary CD73 Antibody TJD5

SHANGHAI, Jan. 22, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China -based clinical stage bio...

2019-01-22 22:04 407

I-Mab Receives U.S. FDA IND Approval for Proprietary Anti-GM-CSF Monoclonal Antibody TJM2

SHANGHAI, Dec. 23, 2018 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a China-based clinical stage bioph...

2018-12-24 11:45 506

I-Mab and CSPC Pharma Announce Strategic Partnership for Long-acting GLP-1 Fc Program

SHANGHAI, Dec. 17, 2018 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China -based clinical stage bio...

2018-12-17 19:10 517

TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs

SHANGHAI, Nov. 29, 2018 /PRNewswire/ -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage bio...

2018-11-29 15:40 759

MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210

SHANGHAI, Nov. 15, 2018 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecD...

2018-11-16 05:01 603

I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy

SHANGHAI, Nov. 2, 2018 /PRNewswire/ -- I-MAB Biopharma Co., Ltd. ("I-Mab"), a Shanghai-based biotec...

2018-11-02 21:11 1375

First Patient Dosing achieved in Mainland China in a Phase II Multi-regional clinical trial (MRCT)

SHANGHAI, Oct. 12, 2018 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a company focusing on innovative...

2018-10-12 14:01 775

I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs

SHANGHAI, Sept. 26, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access bio...

2018-09-26 21:27 841

I-Mab Wins Frost & Sullivan "2018 Best R&D Innovator Award (Biopharma Category)"

SHANGHAI, Sept. 19, 2018 /PRNewswire/ -- I-Mab Biopharma ("I-Mab") announced today that it has been...

2018-09-19 15:33 704

I-Mab's Announces China Clinical Trial Approval of Long-acting hGLP-1 to Treat Type 2 Diabetes

SHANGHAI, Aug. 9, 2018 /PRNewswire/ -- In July, 2018, I-Mab Biopharma (I-Mab) announced that it rec...

2018-08-09 16:16 547

I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202

SHANGHAI, Aug. 7, 2018 /PRNewswire/ -- On August 8, 2018 Beijing time I-Mab Biopharma ("I-Mab"), aS...

2018-08-08 09:01 564

I-Mab Biopharma Announces New CFO

SHANGHAI, July 31, 2018 /PRNewswire/ -- On August 1, 2018 Beijing time, I-Mab Biopharma ("I-Mab"), ...

2018-08-01 08:44 600

I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies

SHANGHAI, July 26, 2018 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a company focusing on innovative...

2018-07-26 21:30 1404

I-Mab Successfully Raised USD 220 Million in Series C Funding

SHANGHAI, June 29, 2018 /PRNewswire/ -- I-Mab Biopharma, a company focusing on innovative Biologics...

2018-06-29 18:36 1262

I-Mab Biopharma Signs Licensing Agreement for HyLeukin With Genexine

- Genexine to receive an upfront payment and entitled to tiered, single-digit royalties on net sale...

2017-12-25 19:50 463

I-Mab Biopharma Partners with MorphoSys on Cancer Investigational Medicine

SHANGHAI, Dec. 1, 2017 /PRNewswire/ -- I-Mab Biopharma (I-Mab) and MorphoSys AG (FSE: MOR; Prime St...

2017-12-01 15:55 526
123